Polatuzumab vedotin-piiq


Polatuzumab vedotin-piiq

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 30 mg/vial, 140 mg/vial)
Drug ClassCD79b-directed antibody-drug conjugate
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater
  • Indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.